PBR Nachrichten

 

The program is intended to assist drug supply chain stakeholders, including FDA, in developing the electronic, interoperable system that will identify and trace certain prescription drugs as they The post IBM, KPMG, Merck and Walmart to assess use o...

Previously known as COR-001, ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). The post Corv...

The FDA has approved Kanjinti for all approved indications of the reference product Herceptin to treat HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal The post FDA approves Amg...

Patients who achieved low disease activity (LDA) with XELJANZ (tofacitinib) extended release (XR) 11 mg once daily (QD) plus methotrexate (MTX) after a 24-week open-label run-in period, were The post Pfizer announces results from XELJANZ XR ORAL Shi...

PhoreMost has identified and validated the target using its next-generation SITESEEKER phenotypic screening technology. Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors The post Vernalis, PhoreMost announc...

The acquisition of Medidata will help Dassault to create its first end-to-end scientific and business platform for life sciences industry. As per terms of the deal, Dassault will The post Dassault Systèmes to buy Medidata Solutions for £4.5bn appear...

The regulator has approved Keytruda as monotherapy and also in combination with a commonly used chemotherapy regimen – platinum and fluorouracil (FU). The approval is for first-line treatment The post FDA extends approval of Merck’s Keyt...

This brings together the expertise of Professor Alessio Ciulli, one of the pioneers in the field of Proteolysis targeting chimeras (PROTACs), based in the School of Life Sciences The post Boehringer Ingelheim, University of Dundee extend anti-cancer...

Having established their collaboration in the 1980s, this extension represents a long-term commitment to patients, offering the benefits of Decapeptyl in the treatment of metastatic and non-metastatic patients The post Debiopharm, Ipsen extend strat...

Cosentyx is claimed to be the first and only fully-human biologic, which directly restricts interleukin-17A (IL-17A), a cornerstone cytokine engaged in the inflammation and development of PsA, psoriasis The post Novartis’ Cosentyx achieves pri...

The accelerated approval for the Polivy, BR combination is for treatment of adult patients with DLBCL whose condition is either relapsed or refractory (R/R) and had been subjected The post Genentech secures FDA accelerated approval for Polivy, BR co...

In the study, PPC-06 met both co-primary endpoints i.e. PASI-75 and IGA scores of 0 or 1 with at least a 2-point reduction from baseline, after 24 weeks The post Dr. Reddy’s announces positive topline results from phase 2b study of PPC-06 in m...

The acquisitions are part of Aptar's strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments. Both The post Aptar acquires Nanopharm and Gateway Ana...

Tilos Therapeutics is involved in the development of therapeutics, which targets the latent TGFβ complex to treat cancer, fibrosis and autoimmune diseases. TGFβ is a potent cytokine supposed The post Merck to buy biopharmaceutical firm Tilos Thera...

As per the terms of the deal, Theramex will have exclusive commercialisation rights for BIJUVA and IMVEXXY outside the US with the exception of Canada and Israel where The post Theramex signs exclusive licensing and supply rights deal with Therapeut...

"We are thrilled to be advancing this strategic alliance with Janssen R&D for connecting biological information to disease condition and therapeutic mechanisms. By pairing the unique data science The post nference enters into R&D data science partne...

All six patients were recruited and treated under this protocol. All primary safety objectives have been achieved at the midpoint in all study participants. As such, the protocol The post ProtoKinetix achieves primary objective safety at midpoint of...

In January 2017, Acucela had received orphan drug designation from the US Food and Drug Administration (FDA) for emixustat to treat Stargardt disease. Stargardt disease is a rare The post Acucela gets European orphan designation for emixustat to tre...

The Calquence, obinutuzumab combination registered a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) during the trial, which was the primary endpoint. This was in comparison to the The post Calquenc...

“Extending the life of transplanted kidneys would mean fewer patients going back on dialysis or needing a second transplant – relieving pressure on waiting lists that in the The post Novartis presents first-of-its-kind histology data wit...